High-dose 131 I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan
ConclusionsHigh-dose131I-MIBG therapy in patients with refractory or relapsed high-risk NBL can provide a favorable prognosis without severe nonhematological toxicities. Better prognosis may be anticipated in patients with the initial good response, no pain at131I-MIBG therapy, no VMA and HVA elevation at131I-MIBG therapy, low Curie score (< 16) just before131I-MIBG therapy, and short time interval (< 3 years) between the initial diagnosis and131I-MIBG therapy.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
More News: Anorexia | Brain | Eating Disorders & Weight Management | Hematology | Japan Health | Neuroblastoma | Neurology | Nuclear Medicine | Pain | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants